Laura Capelli

Medicine & Life Sciences

1. Mutation 100%
2. Non-Small Cell Lung Carcinoma 72%
3. ErbB Receptors 62%
4. Exons 46%
5. Anaplastic Lymphoma Kinase 40%
6. Neoplasms 33%
7. Gastrointestinal Stromal Tumors 29%
8. Stomach 26%
9. Fine Needle Biopsy 25%
10. Protein-Tyrosine Kinases 23%
11. Squamous Cell Carcinoma 22%
12. Stomach Neoplasms 21%
13. High-Throughput Nucleotide Sequencing 20%
14. MAP4 20%
15. Genes 20%
16. Colorectal Neoplasms 19%
17. Liquid Biopsy 17%
18. Erlotinib Hydrochloride 15%
19. Cetuximab 15%
20. Loss of Heterozygosity 14%
21. Papillary Thyroid Cancer 14%
22. Gene Fusion 14%
23. Bevacizumab 13%
24. Soil 13%
25. Adenocarcinoma of Lung 13%
26. Endometriosis 13%
27. Codon 12%
28. Myeloid Cells 12%
29. Seeds 12%
30. Thinking 12%
31. Acute Myeloid Leukemia 11%
32. Early Detection of Cancer 11%
33. Therapeutics 11%
34. Recurrence 11%
35. Patient Selection 10%
36. Canidae 10%
37. Paraffin 10%
38. Prostatic Neoplasms 9%
39. Cell-Free Nucleic Acids 8%
40. Urine 8%
41. Microsatellite Instability 7%
42. Apoptosis 7%
43. Glandular and Epithelial Neoplasms 7%
44. Immunohistochemistry 6%
45. DNA 6%
46. Papillomaviridae 6%
47. Drug Therapy 6%
48. Eph Family Receptors 6%
49. Survival 6%
50. Propidium 5%